新辅助化疗后的腋窝淋巴结管理:综述
本综述探讨可手术乳腺癌新辅助化疗(NAC)后腋窝局部治疗策略。临床淋巴结阴性者NAC后前哨淋巴结活检(SLNB)准确性与前哨SLNB相似,并减少腋窝淋巴结清扫需求;临床淋巴结阳性者获取3枚及以上前哨淋巴结时SLNB准确,但缺乏长期结局;NAC前与后分期对局部区域复发风险的相对重要性仍存争议。
要点
- 临床淋巴结阴性患者NAC后SLNB准确性类似直接SLNB,并减少腋窝淋巴结清扫。
- 临床淋巴结阳性患者NAC后获取3枚及以上前哨淋巴结时SLNB准确,但长期结局缺乏。
- NAC前与后分期对局部区域复发风险的相对重要性仍存争议。
核心结论
- 新辅助化疗减少腋窝淋巴结清扫需求,SLNB是确定NAC后淋巴结状态的准确方法。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 临床淋巴结阴性患者NAC后SLNB准确性类似直接SLNB,并较NAC前SLNB减少腋窝淋巴结清扫需求。
- 临床淋巴结阳性患者中,临床试验显示NAC后获取3枚及以上前哨淋巴结时SLNB准确,但长期结局缺乏。
- NAC前与后分期预测局部区域复发风险的相对重要性仍存争议。
局限性
- 临床淋巴结阳性患者NAC后SLNB准确性的长期结局缺乏。
- NAC前与后分期对局部区域复发风险的相对重要性仍存争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The increasing use of neoadjuvant chemotherapy (NAC) for operable breast cancer has raised questions about optimal local therapy for the axilla. OBSERVATIONS: Sentinel lymph node biopsy (SLNB) after NAC in patients presenting with clinically negative nodes has an accuracy similar to upfront SLNB and reduces the need for axillary lymph node dissection compared with SLNB prior to NAC. In patients presenting with node-positive disease, clinical trials demonstrate that SLNB after NAC is accurate when 3 or more sentinel nodes are obtained, but long-term outcomes are lacking. The relative importance of pre- and post-NAC stage in predicting risk of locoregional recurrence remains an area of controversy. CONCLUSIONS AND RELEVANCE: Neoadjuvant chemotherapy reduces the need for axillary lymph node dissection, and SLNB is an accurate method of determining nodal status after NAC.
引用
- Pilewskie M, Morrow M. Axillary Nodal Management Following Neoadjuvant Chemotherapy: A Review. JAMA Oncol. 2017. PMID: 27918753. doi:10.1001/jamaoncol.2016.4163
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。